Children's National experts showcase sickle cell disease research - Children's National

Andrew Campbell, M.D., director of the Comprehensive Sickle Cell Disease program, assessed the lifetime value of cell and gene therapy (CGTS) through a case study at The American Society of Gene and Cell Therapy's (ASGCT) Annual Meeting.

Dr. Campbell and other Children's National researchers will be presenting again at the Foundation for Sickle Cell Disease Research's (FSCDR) Annual Sickle Cell Disease Research and Educational Symposium, June 7-9, 2024. The symposium includes more than 500 leading researchers, physicians, clinicians and social workers from all over the world.

Here's a look at the presentations from Children's National:

• Dr. Andrew Campbell will provide an update on sickle cell legislation in the U.S., discuss the diagnostic potential of platelet-neutrophil ratio (PNR) for stroke risk in children with sickle cell disease, present a pilot study on increasing naloxone education and prescriptions in sickle cell clinics, and explore the use of platelet to neutrophil ratio as a novel marker for monitoring sickle cell disease patients on hydroxyurea.
• Deepika Darbari, M.D., will collaborate with Dr. Campbell on the presentations regarding platelet-neutrophil ratio and sickle cell disease.
• Steven Hardy, Ph.D., will present on the correlation between VOC and cognitive function using the NIH toolbox in sickle cell disease.
• Regine Hyppolite, MSA, will also collaborate with Dr. Campbell on the presentations regarding platelet-neutrophil ratio and sickle cell disease.